DAVID C HASTINGS
CIK 1237401 · Chief Financial Officer · last filed 2026-01-12
DAVID C HASTINGS is a Chief Financial Officer who has filed 50 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for TRVI, was dated Jan 12, 2026. Across all open-market trades the lifetime net is −$25.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.28M
6
50
-$25.66M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRVI | Chief Financial Officer | — | $14.21 | — | $0 | 1 | 2026-01-12 |
| SCYX | Director | 69,183 | $4.23 | $292.6K | $55.0K | 16 | 2025-06-30 |
| ABUS | Chief Financial Officer | 249,824 | $4.26 | $1.06M | -$95.0K | 9 | 2025-02-19 |
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Director | 0 | $2.19 | $0 | $0 | 7 | 2022-07-11 |
| Unilife Corp (UNIS) Delisted | See Remarks | 300,000 | — | — | $0 | 2 | 2017-01-30 |
| INCY | Chief Financial Officer | 8,500 | $108.53 | $922.5K | -$25.62M | 15 | 2014-02-18 |
Recent Filings
50 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-12 | TRVI | Grant (A) | — | $0 | EDGAR |
| 2025-06-30 | SCYX | Grant (A) | +23,000 | $0 | EDGAR |
| 2025-02-19 | ABUS | Grant (A) | +90,100 | $0 | EDGAR |
| 2025-02-05 | ABUS | Sell (S) | −22,183 | -$72.8K | EDGAR |
| 2024-06-21 | SCYX | Grant (A) | +23,000 | $0 | EDGAR |
| 2024-02-05 | ABUS | Mixed | +102,907 | -$22.2K | EDGAR |
| 2023-06-23 | SCYX | Grant (A) | +10,000 | $0 | EDGAR |
| 2023-06-20 | SCYX | Grant (A) | — | $0 | EDGAR |
| 2023-02-03 | ABUS | Grant (A) | +79,000 | $0 | EDGAR |
| 2022-07-11 | Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Mixed | −49,500 | -$108.9K | EDGAR |